While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

Half a year after being spurned by the FDA and following deep layoffs, IO Biotech has decided to close its doors for good.

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only ...

Why Enveda, Faeth Therapeutics, Gilgamesh Pharma, and Argo Biopharma are among the most innovative companies in biotech right ...

Lipella Pharmaceuticals, a biotechnology company in Pittsburgh’s Homewood neighborhood, filed for bankruptcy protection ...

Headwinds in the sector are clearing. That is good news for venture firms seeking liquidity and for a stock market looking ...

Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale amid strong one-year stock ...

The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing ...

Noah Keating said the tissue regeneration firm he worked at returned from the United Arab Emirates to the Manchester Millyard after New Hampshire last year adopted a Right-to-Try law to allow ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force behind this resurgence.

This little-known biotech could have a big hit on its hands with VK2735, a GLP-1 weight loss drug candidate.